Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued on Sunday. The brokerage set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Stock Performance

NASDAQ RKDA opened at $3.15 on Friday. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $10.31. The stock has a market capitalization of $4.30 million, a PE ratio of -0.74 and a beta of 0.86. The stock has a 50-day simple moving average of $4.33 and a 200 day simple moving average of $4.11.

Hedge Funds Weigh In On Arcadia Biosciences

An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC acquired a new position in shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned about 0.90% of Arcadia Biosciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.73% of the company’s stock.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.